Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZEZachary D. Epstein‐PetersonKHKelly HanniganWJW. Thomas Johnson

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates improved overall survival with targeted treatments in T-cell lymphomas.

Key Points

  • This research aims to evaluate the outcomes of second-line systemic therapy for relapsed peripheral T-cell lymphomas.
  • Retrospective analysis of patients treated with second-line therapy between 2012-2025.
  • Categorized treatments as non-chemotherapy, chemotherapy, or combinations.
  • Utilized Kaplan-Meier methods for survival calculations.
  • Employed univariable and multivariable Cox models to associate clinical features with survival outcomes.
  • Identified 212 patients with relapsed peripheral T-cell lymphomas.
  • Median progress-free survival was 4.7 months, and overall survival was 22.7 months.
  • Overall response rate to second-line therapy was 63%, with 42% achieving complete response.
  • Poorer outcomes were associated with nodal subtypes not specified and primary refractory disease.

Cite This Study

Epstein‐Peterson et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2d6https://doi.org/10.1182/blood-2025-5412
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents2025 · 2 citations
  2. 2Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy2025
  3. 3Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status2025
  4. 4Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry2025
  5. 5TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom2025